Biogen Idec Inc (BIIB) 290.84 $BIIB
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Stock Market News for April 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:06AM CDT
Disappointing corporate earnings results and escalating tension between Russia and Ukraine dragged the benchmarks down on Friday
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Global Hemophilia B Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrpb8k/hemophilia_b) has announced the addition of the "Global Hemophilia B Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Emergent BioSolutions Inc. - Sangamo BioSciences, Inc. - Novo Nordisk A/S - rEVO Biologics - Pfizer Inc. - OPKO Health, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Catalyst Biosciences, Inc. - Amarna Therapeutics B.V. - Asklepios BioPharmaceutical, Inc. - LFB Biotechnologies, S.A.S - UniQure NV - AlphaMab Co., Ltd Drug Profiles - coagulation factor IX-Fc (recombinant) - coagulation factor IX (recombinant) - GNR-001 - trenonacog alfa - coagulation factor IX-Fc (recombinant) - trenonacog alfa - CSL-654 - NN-7999 - LR-769 - BAX-817 - nonacog alfa biosimilar - AMT-060 - AskBio-009 - Gene Therapy For Hemophilia B - CSL-689 - PF-05280602 - concizumab - Gene Therapy To Activate Factor IX For Hemophilia B - MOD-9017 - MOD-5017 - ALN-AT3 - eptacog alfa biosimilar - Factor IX - ZFP Nucleases for Hemophilia - IB1-007 - Long Acting Blood Coagulation Factor IX - Long Acting Coagulation Factor VIIa - CB-2679d - MOD-5014 - Gene Therapy For Hemophilia B - AZ-10047130 - AZ-10776241 - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/mr...mophilia_b
Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 3.06% Loss
Comtex SmarTrend(R) - Fri Apr 25, 4:01PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 3.06% Yesterday
Comtex SmarTrend(R) - Fri Apr 25, 4:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PharmaPoint: Crohn's Disease - Current and Future Players
M2 - Fri Apr 25, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n3bcj/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - Current and Future Players" report to their offering. PharmaPoint: Crohn's Disease - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Crohn's Disease - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Crohn's Disease sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - Appendix Companies Mentioned - Johnson & Johnson - AbbVie - UCB - Biogen Idec - Takeda - ChemoCentryx For more information visit http://www.researchandmarkets.com/research/4n...harmapoint
Quintiles enters into comprehensive clinical development partnership with Biogen Idec
M2 - Fri Apr 25, 6:01AM CDT
Biopharmaceutical company Quintiles revealed on Thursday the launch of a multi year strategic clinical development agreement with Biogen Idec (NasdaqGS:BIIB).
Why Xilinx Inc., Biogen Idec Inc., and Qualcomm Incorporated Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Thu Apr 24, 7:04PM CDT
U.S. manufacturers are starting to hit their strides this spring, according to new data from the Census Bureau. Durable goods orders rose 2.6% in March from February, notably better than the 2% increase expected by Econoday; the strong demand is a...
Why Investors Should Love Biogen's Earnings Miss
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Big biotech Biogen Idec has weathered the industry's storm in a rocky 2014. The stock's gained more than 9% despite the biotech sector's fall brought on by nervous investors concerned about the market's rally, and Biogen has plenty of room for...
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Earnings Roundup: Biogen's Tecfidera Wins More Share
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
Biogen remains a market leader in treating multiple sclerosis, an autoimmune disease that affects more than 1.1 million people in the U.S. and Europe. The company has launched a host of widely successful MS therapies over the past decade,...
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:44AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rally nearly 10.00% on the day.
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership
Business Wire - Thu Apr 24, 7:00AM CDT
Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec (NASDAQ: BIIB) have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes.
Biogen EPS misses, guides up
at Investor's Business Daily - Wed Apr 23, 5:49PM CDT
The biotech's Q1 EPS jumped 25% to $2.47, but missed views by 9 cents. Revenue rose 50.5% to $2.13 bil, above views for $2 bil. U.S. sales of MS drug Tecfidera were $460 mil vs. views of $413 mil. Nearly all individual product sales beat consensus....
Biogen Q1, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 5:46PM CDT
Big-cap biotech Biogen Idec reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock rose just a fraction as biotechs had a bad day and Biogen revealed it's being probed by authorities. Biogen (BIIB)...
Why Biogen (BIIB) Stock Is Down Today
at The Street - Wed Apr 23, 12:55PM CDT
Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Stock Market News for April 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:06AM CDT
Disappointing corporate earnings results and escalating tension between Russia and Ukraine dragged the benchmarks down on Friday
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Global Hemophilia B Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrpb8k/hemophilia_b) has announced the addition of the "Global Hemophilia B Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Emergent BioSolutions Inc. - Sangamo BioSciences, Inc. - Novo Nordisk A/S - rEVO Biologics - Pfizer Inc. - OPKO Health, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Catalyst Biosciences, Inc. - Amarna Therapeutics B.V. - Asklepios BioPharmaceutical, Inc. - LFB Biotechnologies, S.A.S - UniQure NV - AlphaMab Co., Ltd Drug Profiles - coagulation factor IX-Fc (recombinant) - coagulation factor IX (recombinant) - GNR-001 - trenonacog alfa - coagulation factor IX-Fc (recombinant) - trenonacog alfa - CSL-654 - NN-7999 - LR-769 - BAX-817 - nonacog alfa biosimilar - AMT-060 - AskBio-009 - Gene Therapy For Hemophilia B - CSL-689 - PF-05280602 - concizumab - Gene Therapy To Activate Factor IX For Hemophilia B - MOD-9017 - MOD-5017 - ALN-AT3 - eptacog alfa biosimilar - Factor IX - ZFP Nucleases for Hemophilia - IB1-007 - Long Acting Blood Coagulation Factor IX - Long Acting Coagulation Factor VIIa - CB-2679d - MOD-5014 - Gene Therapy For Hemophilia B - AZ-10047130 - AZ-10776241 - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/mr...mophilia_b
Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 3.06% Loss
Comtex SmarTrend(R) - Fri Apr 25, 4:01PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Biogen Idec to Potentially Rebound After Falling 3.06% Yesterday
Comtex SmarTrend(R) - Fri Apr 25, 4:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.58 to a high of $296.74. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $286.48 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PharmaPoint: Crohn's Disease - Current and Future Players
M2 - Fri Apr 25, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4n3bcj/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - Current and Future Players" report to their offering. PharmaPoint: Crohn's Disease - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Crohn's Disease - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Crohn's Disease sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - Appendix Companies Mentioned - Johnson & Johnson - AbbVie - UCB - Biogen Idec - Takeda - ChemoCentryx For more information visit http://www.researchandmarkets.com/research/4n...harmapoint
Quintiles enters into comprehensive clinical development partnership with Biogen Idec
M2 - Fri Apr 25, 6:01AM CDT
Biopharmaceutical company Quintiles revealed on Thursday the launch of a multi year strategic clinical development agreement with Biogen Idec (NasdaqGS:BIIB).
Why Xilinx Inc., Biogen Idec Inc., and Qualcomm Incorporated Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Thu Apr 24, 7:04PM CDT
U.S. manufacturers are starting to hit their strides this spring, according to new data from the Census Bureau. Durable goods orders rose 2.6% in March from February, notably better than the 2% increase expected by Econoday; the strong demand is a...
Why Investors Should Love Biogen's Earnings Miss
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Big biotech Biogen Idec has weathered the industry's storm in a rocky 2014. The stock's gained more than 9% despite the biotech sector's fall brought on by nervous investors concerned about the market's rally, and Biogen has plenty of room for...
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Earnings Roundup: Biogen's Tecfidera Wins More Share
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
Biogen remains a market leader in treating multiple sclerosis, an autoimmune disease that affects more than 1.1 million people in the U.S. and Europe. The company has launched a host of widely successful MS therapies over the past decade,...
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:44AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rally nearly 10.00% on the day.
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership
Business Wire - Thu Apr 24, 7:00AM CDT
Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec (NASDAQ: BIIB) have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes.
Biogen EPS misses, guides up
at Investor's Business Daily - Wed Apr 23, 5:49PM CDT
The biotech's Q1 EPS jumped 25% to $2.47, but missed views by 9 cents. Revenue rose 50.5% to $2.13 bil, above views for $2 bil. U.S. sales of MS drug Tecfidera were $460 mil vs. views of $413 mil. Nearly all individual product sales beat consensus....
Biogen Q1, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 5:46PM CDT
Big-cap biotech Biogen Idec reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock rose just a fraction as biotechs had a bad day and Biogen revealed it's being probed by authorities. Biogen (BIIB)...
Why Biogen (BIIB) Stock Is Down Today
at The Street - Wed Apr 23, 12:55PM CDT
Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today
